Loading clinical trials...

How Abnormal Function of Fat Tissue in Type 1 Diabetes Contributes to Fat in the Liver | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGNA

How Abnormal Function of Fat Tissue in Type 1 Diabetes Contributes to Fat in the Liver

The Impact of Adipose Tissue Insulin Resistance and Abdominal Obesity on Hepatic Fatty Acid Metabolism in Type 1 Diabetes

NCT07133854•Université de Sherbrooke

View on ClinicalTrials.gov

Summary

Steatotic liver disease associated with metabolic dysfunction (MASLD) is a disease caused by excess fat storage in the liver. Excessive fat delivery to the liver and MASLD typically occurs in people with abdominal obesity and type 2 diabetes. Type 1 diabetes (T1D) is also associated with a marked increase in the release of fat from adipose tissues and MASLD is increased in T1D and significantly increases the risk of heart, kidney and eye diseases.

Detailed Description

It is a parallel study design between T1D and controls. The outcomes will be assessed between T1D vs. controls during the metabolic visit. The metabolic visit will last 9 hours: it will be a test meal with perfusion of stable tracers, blood sampling, PET acquisitions using radiopharmaceuticals (18FTHA and 11C-palmitate) and MRI acquisitions. In total, 32 participants will be recruited: * 16 living with T1D and abdominal obesity * 16 with normoglycemia

Eligibility

Age

21 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•16 individuals living with T1D and abdominal obesity, as defined by the International Diabetes Federation country/ethnic group-specific criteria (https://www.idf.org/e-library/consensus-statements/60- \[1\]. Treatment for T1D will be intensive insulin therapy on continuous pump perfusion with continuous glucose monitoring.
•16 individuals with normoglycemia (i.e., HbA1c below 6.0%) matched for sex, age (± 5 years), waist circumference (± 3 cm), and menopausal status.

Exclusion Criteria

•less than 70% of time in glycemic range (for T1D);
•history of primary dyslipidemia (LDL-cholesterol over 5 mmol/L or TG over 10 mmol/L) or uncontrolled high blood pressure (over 160/100 mmHg) precluding the withdrawal of lipid lowering and anti-hypertensive agents as per protocol;
•presence of overt cardiovascular, liver or renal disease (except microalbuminuria without reduced kidney function), or other uncontrolled medical conditions;
•use of any medication other than insulin that may affect lipid or carbohydrate metabolism and that cannot be stopped prior to testing;
•current or planned pregnancy within the next 6 months;
•any contraindication to MRI.
•Being allergic to eggs
•Smoking (\>1 cigarette/day) and/or consumption of \>2 alcoholic beverages per day
•Having participated to a research study with exposure to radiation in the last year before the start of the study

Locations (1)

Centre de recherche du CHUS

Sherbrooke, Quebec, Canada

Key Dates

Start Date

September 1, 2026

Primary Completion Date

September 1, 2027

Completion Date

December 1, 2028

Last Updated

August 21, 2025

Enrollment

ESTIMATED participants

Conditions

Metabolic Dysfunction-Associated Steatotic Liver DiseaseNon-Alcoholic Steato-Hepatitis (NASH)Type 1 Diabetes Mellitus

Interventions

Imaging PET/MRI

DIAGNOSTIC_TEST

Stable isotope infusions

DIAGNOSTIC_TEST

meal test

DIAGNOSTIC_TEST

Indirect calorimetry

DIAGNOSTIC_TEST

Contacts

Frédérique Frisch

CONTACT

+1-819-346-1110 frederique.frisch@usherbrooke.ca

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View study

RECRUITING

Spleen Stiffness Measurement for the Detection of Advanced Fibrosis

NCT07440511

MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 21, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

How Abnormal Function of Fat Tissue in Type 1 Diabetes Contributes to Fat in the Liver

Inclusion Criteria

Exclusion Criteria

Feasibility of a Tailored Online Self-compassion Intervention

Spleen Stiffness Measurement for the Detection of Advanced Fibrosis

Study of the Link Between MASH ( Metabolic Dysfunction-Associated Steatohepatitis) and MAMs (Mitochondria-Associated Membranes ) Alteration in Patients Undergoing Bariatric Surgery - MAMBA

Implementing the Spotlight AQ Platform in Adolescent/ Young Adult (16-25 Years Old) Type 1 Diabetics (T1D)

The Effects of Fluoxetine and/or DHEA

Fake Carbs Practice With AID System - MiniMed 780G in Children and Adolescents With T1D.